echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Seagen and Sanofi reach cooperation to develop multiple anti-cancer ADCs

    Seagen and Sanofi reach cooperation to develop multiple anti-cancer ADCs

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 16, 2022, Seagen and Sanofi announced an exclusive collaboration agreement to design, develop and commercialize antibody drug conjugates (ADCs) against up to three cancer targets


    ADCs consist of three parts: monoclonal antibodies targeting specific antigens on the tumor surface, cytotoxic drugs that can kill tumor cells, and linkers that connect the cytotoxic drugs to the antibody


    Under the terms of the partnership, Seagen and Sanofi will jointly fund global development activities and share equally in any future profits


    References:

    [1] Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.